/XOMAP
XOMAP Stock - XOMA Corporation
Healthcare|BiotechnologyNASDAQ
$26.57-0.69%
$0.18 (-0.69%) • Dec 19
64
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.53
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).70
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.82
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+10.0%upside
Target: $29.22
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for XOMAP
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$26.30 – $26.83
TARGET (TP)$30.55
STOP LOSS$24.44
RISK/REWARD1:1.9
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta0.94
52W High$30.00
52W Low$24.96
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $28.49M | $4.76M | $6.03M | $38.16M | $29.39M |
| Gross Profit | $28.28M | $4.62M | $5.75M | $37.99M | $29.21M |
| Gross Margin | 99.3% | 97.0% | 95.5% | 99.6% | 99.4% |
| Operating Income | $-39,976,000 | $-41,848,000 | $-17,414,000 | $17.53M | $12.42M |
| Net Income | $-13,821,000 | $-40,831,000 | $-17,104,000 | $15.80M | $13.30M |
| Net Margin | -48.5% | -858.2% | -283.8% | 41.4% | 45.3% |
| EPS | $-1.65 | $-4.04 | $-1.98 | $0.69 | $0.82 |
Company Overview
XOMA Corporation operates as a biotechnology royalty aggregator in Europe, the United States, and the Asia Pacific. The company engages in helping biotech companies for enhancing human health. It acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceutical or biotechnology companies. The company focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners. It has a portfolio with approximately 70 assets. XOMA Corporation was incorporated in 1981 and is headquartered in Emeryville, California.
Visit WebsiteLoading analyst ratings...
Earnings History & Surprises
XOMAPBeat Rate
75%
Last 4 quarters
Avg Surprise
+681.3%
EPS vs Estimate
Beats / Misses
3/1
Last 12 quarters
Latest EPS
$0.78
Q4 2025
EPS Surprise History
Q1 24
No data
Q2 24
No data
Q3 24
No data
Q4 24
No data
Q1 25
-16.5%
$-0.33vs$-0.29
Q2 25
+183.2%
$0.20vs$-0.24
Q3 25
+508.7%
$0.61vs$-0.15
Q4 25
+2050.0%
$0.78vs$-0.04
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 11, 2026 | — | — | — | — |
Q1 2026 | Mar 16, 2026 | — | — | — | — |
Q4 2025 | Nov 12, 2025 | $-0.04 | $0.78 | +2050.0% | ✓ BEAT |
Q3 2025 | Aug 15, 2025 | $-0.15 | $0.61 | +508.7% | ✓ BEAT |
Q2 2025 | May 13, 2025 | $-0.24 | $0.20 | +183.2% | ✓ BEAT |
Q1 2025 | Mar 17, 2025 | $-0.29 | $-0.33 | -16.5% | ✗ MISS |
Q4 2024 | Nov 7, 2024 | — | $-1.47 | — | — |
Q3 2024 | Aug 13, 2024 | — | $0.92 | — | — |
Q2 2024 | May 9, 2024 | — | $-0.74 | — | — |
Q1 2024 | Mar 8, 2024 | — | $-1.75 | — | — |
Q1 2024 | Mar 6, 2024 | — | $-0.48 | — | — |
Q3 2023 | Aug 8, 2023 | — | $-0.47 | — | — |
Q2 2023 | May 9, 2023 | — | $-1.55 | — | — |
Q1 2023 | Mar 9, 2023 | — | $-0.52 | — | — |
Q4 2022 | Nov 3, 2022 | — | $-0.35 | — | — |
Q3 2022 | Aug 4, 2022 | — | $-0.40 | — | — |
Q2 2022 | May 5, 2022 | — | $-0.22 | — | — |
Q1 2022 | Mar 8, 2022 | — | $2.63 | — | — |
Q4 2021 | Nov 4, 2021 | — | $-0.39 | — | — |
Q3 2021 | Aug 5, 2021 | — | $-0.20 | — | — |
Latest News
Loading news...
Frequently Asked Questions about XOMAP
What is XOMAP's current stock price?
XOMA Corporation (XOMAP) is currently trading at $26.57 per share. The stock has moved -0.69% today.
What is the analyst price target for XOMAP?
No analyst price targets are currently available for this stock.
What sector is XOMA Corporation in?
XOMA Corporation operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is XOMAP's market cap?
XOMA Corporation has a market capitalization of $0.32 billion, making it a small-cap company.
Does XOMAP pay dividends?
No, XOMA Corporation does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorACIU
AC Immune S.A.
$3.03
Mkt Cap: $0.3B
ALDX
Aldeyra Therapeutics, Inc.
$4.96
Mkt Cap: $0.3B
AMRN
Amarin Corporation plc
$13.80
Mkt Cap: $0.3B
CLLS
Cellectis S.A.
$4.37
Mkt Cap: $0.4B
GNLX
Genelux Corporation
$4.20
Mkt Cap: $0.2B
KYTX
Kyverna Therapeutics, Inc.
$7.19
Mkt Cap: $0.3B
LRMR
Larimar Therapeutics, Inc.
$3.65
Mkt Cap: $0.3B
LYEL
Lyell Immunopharma, Inc.
$33.33
Mkt Cap: $0.7B
SLN
Silence Therapeutics plc
$6.37
Mkt Cap: $0.3B
TECX
Tectonic Therapeutic, Inc.
$19.56
Mkt Cap: $0.4B
Explore stocks similar to XOMAP for comparison